Trial Profile

AA Phase 2, Randomized, Double-Blinded Study of the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide (Primary) ; Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat
Indications HIV-1 infections
Focus Therapeutic Use
Sponsors Gilead Sciences

08 Sep 2016 Status changed from active, no longer recruiting to completed.
14 Mar 2016 Planned End Date changed from 1 Jan 2016 to 1 May 2016 as per ClinicalTrials.gov record.
25 Feb 2016 Results (post hoc pooled analysis of GS-US292-0102 and GS-US292-0104 studies, n = 1733) assessing long term renal safety presented at the 23rd Conference on Retroviruses and Opportunistic Infections.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com